News & Updates

Patients with type 2 diabetes (T2D) who use glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) appear to have no increased risk of suicidality when compared with the use of dipeptidyl peptidase-4 inhibitors (DPP-4is) or sodium-glucose cotransporter-2 inhibitors (SGLT-2is), a study has found.

Treatment with a digital cognitive behavioural therapy (CBT), dubbed Almee, demonstrates a clinically meaningful improvement in pulmonary fibrosis (PF)-related anxiety and is well-tolerated by patients, reports a study.